SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
(4) - EconoTimes)
SAN DIEGO, Aug. 14, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that its Compensation Committee granted inducement awards pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules on July 31, 2017, August 7, 2017 and August 14, 2017 consisting of stock options to purchase an aggregate of 65,000 shares to three new employees. Each stock option has an exercise price per share equal to the closing price of Retrophin's common stock on the date of grant, is a non-qualified stock option, has a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date and the remaining three-fourths vesting over the following three years in twelve equal quarterly installments.
Each stock option described above is subject to the terms of Retrophin's 2015 Equity Incentive Plan, but was granted outside of the 2015 Equity Incentive Plan, and was granted as an inducement material to each new employee entering into employment with Retrophin in accordance with NASDAQ Listing Rule 5635(c)(4).
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.
Contact: Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 760-260-8600 [email protected]
